Higuchi 2012.

Trial name or title	Randomized phase III study of S‐1 plus oxaliplatin versus S‐1 plus cisplatin for first‐line treatment of advanced gastric cancer
Methods	RCT 2 arms
Participants	N = 685 with unresectable advanced or recurrent gastric cancer, PS 0‐2, age ≥ 20 years
Interventions	Arm A (SOX): (oral S‐1 40 mg/m² twice a day d 1‐14 + oxaliplatin 100 mg/m² iv day 1, repeated at 3 weeks) versus Arm B (SP): (oral S‐1 40 mg/m² twice a day d 1‐ 21 + cisplatin 60 mg/m² iv day 8, repeated at 5 weeks)
Outcomes	Progression‐free survival, response rate (RR), safety, and length of hospital stay per cycle
Starting date
Contact information	Yakult Honsha Co., Ltd., Clinical Development, Medical Development Department, Pharmaceutical Division, Tel 813‐5550‐8966 Fax 813‐3248‐5502
Notes	The study is registered (JapicCTI‐101021) and has recruited 685 participants from January 2010 and October 2011.